InMed Pharmaceuticals Inc. INM
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | 3.25M | 4.51M | 4.80M | 4.94M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 3.25M | 4.51M | 4.80M | 4.94M |
| Cost of Revenue | -- | 1.35M | 2.44M | 2.45M | 2.51M |
| Gross Profit | -- | 587.40K | 763.00K | 1.04M | 1.13M |
| SG&A Expenses | -- | 6.15M | 5.74M | 5.84M | 5.80M |
| Depreciation & Amortization | -- | 210.30K | 210.90K | 210.90K | 212.30K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | 10.53M | 11.09M | 11.47M | 11.60M |
| Operating Income | -- | -8.59M | -7.89M | -7.97M | -7.96M |
| Income Before Tax | -- | -8.38M | -7.71M | -8.26M | -8.21M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -8.38 | -7.71 | -8.26 | -8.21 |
| Earnings from Discontinued Operations | -- | -128.30K | 46.30K | 46.30K | 46.30K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -8.51M | -7.66M | -8.21M | -8.16M |
| EBIT | -- | -8.59M | -7.89M | -7.97M | -7.96M |
| EBITDA | -- | -8.38M | -7.68M | -7.76M | -7.75M |
| EPS Basic | -- | -2.88 | -4.08 | -7.22 | -9.48 |
| Normalized Basic EPS | -- | -1.79 | -2.57 | -4.53 | -5.95 |
| EPS Diluted | -- | -2.88 | -4.08 | -7.22 | -9.48 |
| Normalized Diluted EPS | -- | -1.79 | -2.57 | -4.53 | -5.95 |
| Average Basic Shares Outstanding | -- | 13.45M | 10.50M | 7.25M | 3.91M |
| Average Diluted Shares Outstanding | -- | 13.45M | 10.50M | 7.25M | 3.91M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |